Axsome Therapeutics Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $218.4M | $191.2M | $196.0M | $171.0M | $150.0M | $121.5M | $118.8M | $104.8M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $46.2M | $52.7M | $48.8M | $40.2M | $49.5M | $44.8M | $55.0M | $45.4M |
| SG&A Expense | $208.1M | $185.0M | $169.3M | $150.2M | $130.3M | $120.8M | $113.3M | $95.6M |
| Operating Income | $-49.6M | $-63.4M | $-27.0M | $-46.1M | $-36.7M | $-57.0M | $-72.6M | $-62.6M |
| Operating Margin | -22.7% | -33.1% | -13.8% | -27.0% | -24.5% | -46.9% | -61.1% | -59.8% |
| Interest Expense | $-3.2M | $3.1M | $-13.7M | $-3.4M | $-4.1M | $5.3M | $-5.4M | $-5.7M |
| Pretax Income | $-51.2M | $-64.5M | $-28.1M | $-47.2M | $-48.9M | $-59.4M | $-74.8M | $-64.6M |
| Income Tax Expense | $128.0K | $0 | $430.0K | $0 | $-960.0K | $0 | $85.0K | $0 |
| Net Income | $-51.3M | $-64.5M | $-28.6M | $-47.2M | $-48.0M | $-59.4M | $-74.9M | $-64.6M |
| Net Margin | -23.5% | -33.8% | -14.6% | -27.6% | -32.0% | -48.9% | -63.1% | -61.7% |
| EPS (Basic) | $-0.99 | $-1.26 | $-0.55 | $-0.94 | $-0.97 | $-1.22 | $-1.54 | $-1.34 |
| EPS (Diluted) | $-0.99 | $-1.26 | $-0.55 | $-0.94 | $-0.97 | $-1.22 | $-1.54 | $-1.34 |
| Shares Outstanding (Basic) | 51.8M | 51.2M | 49.7M | 50.0M | 49.4M | 48.9M | 47.9M | 48.1M |
| Shares Outstanding (Diluted) | 51.8M | 51.2M | 49.7M | 50.0M | 49.4M | 48.9M | 47.9M | 48.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |